HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, [11beta,16alpha]

HCID 470826
New reaction
Print
Basic informationNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
51333-22-3
Standard SMILES
CCCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1
InChIKey
ZLJUJADSMLOUDO-UQDRGZAPSA-N
Molecular formula
C26H36O6
Average molar mass
444.6 g/mol
Monoisotopic mass
444.25118886

Names & identifiers

Preferred name
Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, [11beta,16alpha]
IUPAC
(1S,2S,4R,8S,9S,11S,12S,13R)-6-butyl-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
English name
Budesonide
Molecular formula
C25H34O6
Molecular weight
430.53

Names & synonyms

butyl-hydroxy-(2-hydroxyacetyl)-dimethyl-[?]onePregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, [11.beta.,16.alpha.]PULMICORTBudesonide CRSBudesonRespulesRHINOCORTBudenofalkBIDIENS-1320EntocortMicronyl

Database identifiers

CAS
51333-22-3
PubChem CID
470826

Properties

Computed structural properties

XLogP
3.1
Topological polar surface area
93.1 Ų
Hydrogen bond donors
2
Hydrogen bond acceptors
6
Rotatable bonds
5
Heavy atoms
32
Formal charge
0
Complexity
878

Physicochemical properties

Melting point
221 · 221-232°C (dec.)
Boiling point
464.79 °C · 464.79°C (rough estimate)
alpha
25 · D25 +98.9° (c = 0.28 in methylene chloride)
Density
1.1046 · 1.1046 (rough estimate)
refractive index
1.4593 · 1.4593 (estimate)
storage temp.
Store at RT
solubility
Practically insoluble in water, freely soluble in methylene chloride, sparingly soluble in ethanol (96 per cent).
form
powder
pka
12.87 · 12.87±0.10(Predicted)
color
White to Off-White
Water Solubility
21.53 mg/L · 21.53mg/L(temperature not stated)
Merck
14 · 14,1468
BCS Class
2 · 2
InChIKey
VOVIALXJUBGFJZ-KWVAZRHASA-N
SMILES
[H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]4(C)[C@@]2([H])C[C@H]5OC(CCC)O[C@@]45C(=O)CO

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Safety data

PPE
Eyeshields, Gloves, type N95 (US)
wgk
3
rtecs
TU3723000
hs_code
29372900
Toxicity
LD50 oral in rat: > 3200mg/kg
risk_code
40-36/37/38-20/21/22
Signal word
Danger
Symbol(GHS)
GHS08,GHS07
hazard_code
Xn
safety_code
22-36-26
Storage Class
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
target organs
Adrenal gland
Hazard statements
H361-H332-H317-H334-H312
Hazard Classifications
Acute Tox. 4 OralAquatic Chronic 3Repr. 2Skin Sens. 1STOT RE 1 Inhalation
Precautionary statements
P261-P272-P280-P302+P352-P333+P313-P321-P363-P501-P201-P202-P281-P308+P313-P405-P501-P261-P271-P304+P340-P312-P280-P302+P352-P312-P322-P363-P501-P261-P285-P304+P341-P342+P311-P501
Hazardous Substances Data
51333-22-3(Hazardous Substances Data)

Chemistry & industry

Applications · 9 items

DescriptionBudesonide (brand name: Pulmicort) is a synthetic corticosteroid medication. It is indicated for the maintenance and prophylactic treatment of asthma. It is also used for the long-term management of chronic obstructive pulmonary disease (COPD). It is also useful for the treatment of inflammatory bowel disease including Crohn’s disease, ulcerative colitis and microscopic colitis, and also for treating allergic rhinitis. It exhibits potent glucocorticoid activity and weak mineralocorticoid activity in vivo. It is effective in inhibiting the activities of multiple cell types and mediators participating in either allergic or non-allergic-mediated inflammation.

DescriptionBudesonide is a glucocorticoid and an agonist of glucocorticoid receptors (EC50 = 45.7 pM in a transactivation assay). It is selective for glucocorticoid over mineralocorticoid receptors (EC50 = 7,620 pM). Budesonide inhibits LPS-induced TNF-α release from human peripheral blood mononuclear cells (PBMCs; IC50 = 0.96 nM). It reduces levels of IL-1β and eotaxin in the lungs and the number of eosinophils and neutrophils in bronchoalveolar lavage fluid (BALF) in a rat model of ovalbumin-induced airway inflammation when administered at a dose of 3 mg/kg. Intracolonic administration of budesonide decreases colon wet weight and colonic myeloperoxidase (MPO) activity in a rat model of oxazolone-induced colitis. Formulations containing budesonide have been used in the treatment of Crohn''s disease, ulcerative colitis, allergic rhinitis, and asthma.

DescriptionBudesonide is composed of a 1:1 mixture of epimers of the 16,17-butylacetal, creating a chiral center. The 22R-epimer binds to the GR with higher affinity than does the 22S-epimer (Table 33.5). The butyl acetal chain provided the highest potency for the homologous acetal chains. Its rate of topical uptake into epithelial tissue is more than 100 times faster than that for hydrocortisone and dexamethasone. Approximately 85% of the IV administered dose of budesonide undergoes extensive first-pass hepatic metabolism by CYP3A4 to its primary metabolites, 6β-hydroxybudesonide and 16α-hydroxyprednisolone, which have approximately 1/100 the potency of budesonide. This is an important inactivation step in limiting budesonide's systemic effect on adrenal suppression.

UsesA non-halogenated glucocorticoid related to triamcinolone hexacetonide. Used as an antiinflammatory agent

laxative, antineoplastic

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
CAS DataBase Reference
51333 · 51333-22-3(CAS DataBase Reference)
NCI Dictionary of Cancer Terms
budesonide
FDA UNII
3 OKS62Q6X · Q3OKS62Q6X
ATC code
7 EA06,D07AC09,R01AD05,R03BA02 · A07EA06,D07AC09,R01AD05,R03BA02
UNSPSC Code
12352200 · 12352200
NACRES
77 · NA.77
Protein binding
85 · 85-90%
Volume of distribution
3 · 3(L/kg)
Biological half-life
1.8 · 1.8-2.2 (inhaled), 3-4 (oral) / -
Symbol(GHS)
8 · GHS08,GHS07
Signal word
Danger
Hazard statements
361 · H361-H332-H317-H334-H312
Precautionary statements
261 · P261-P272-P280-P302+P352-P333+P313-P321-P363-P501-P201-P202-P281-P308+P313-P405-P501-P261-P271-P304+P340-P312-P280-P302+P352-P312-P322-P363-P501-P261-P285-P304+P341-P342+P311-P501
target organs
Adrenal gland
PPE
95 · Eyeshields, Gloves, type N95 (US)
Hazard Codes
Xn
Risk Statements
40 · 40-36/37/38-20/21/22
Safety Statements
22 · 22-36-26
WGK Germany
3 · 3
RTECS
3723000 · TU3723000
HS Code
29372900 · 29372900
Storage Class
6.1 C · 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
Hazard Classifications
4 OralAquatic · Acute Tox. 4 OralAquatic Chronic 3Repr. 2Skin Sens. 1STOT RE 1 Inhalation
Hazardous Substances Data
51333 · 51333-22-3(Hazardous Substances Data)
Toxicity
50 oral · LD50 oral in rat: > 3200mg/kg
Uses

UsesThe oral capsule is used for the treatment of mild to moderate active Crohn's disease. The oral tablet is used for induction of remission in patients with active, mild to moderate ulcerative colitis. The oral inhalation formulation is used for the treatme

UsesBudesonide is a glucocorticoid steroid that activates the glucorcorticoid receptor with an EC50 value of 12.4 nM. Like other glucocorticoids, budesonide reduces inflammation and has utility in inflammatory diseases, like asthma and inflammatory bowel disease. Also like other glucocorticoids, budesonide may be abused by athletes.[Cayman Chemical]

General DescriptionBudesonide (Pulmicort Turbohaler,Rhinocort) is extensively metabolized in the liver, with 85%to 95% of the orally absorbed drug metabolized by the firstpasseffect. The major metabolites are 6β-hydroxybudesonideand 16α-hydroxyprednisolone, both with less than1% of the activity of the parent compound. Metabolism involvesthe CYP3A4 enzyme, so coadministration of budesonidewith a known CYP3A4 inhibitor should be monitoredcarefully.

General DescriptionBudesonide, 16α,17-[butylidenebis-(oxy)]-11β,21-dihydroxypregna-1,4-diene-3, 20-dione (Entocort), in oral capsules is used to treat Crohn disease. Theaffinity for the GC is approximately 200-fold greater than thatof hydrocortisone and 15-fold greater than that of prednisolone.Budesonide is a mixture of epimers, with the 22Rform having twice the affinity for the GR of the S epimer.This GC is metabolized by CYP3A4, and its levels can be increasedin the presence of potent CYP3A4 inhibitors.Budesonide is also used in an inhaled formulation for thetreatment of asthma.

Upstream & downstream products

Upstream raw materials

Hydrogen fluorideButyraldehyde

Additional notes

DefinitionChEBI: A glucocorticoid steroid having a highly oxygenated pregna-1,4-diene structure. It is used mainly in the treatment of asthma and non-infectious rhinitis and for treatment and prevention of nasal polyposis.